PMC6220405_01
Patient's weight for age and height for age on CDC growth charts after being 17 years old.
CRIE2018-4748750.001.jpg
PMC6220405_01_CRIE2018-4748750.001.jpg
fig1
TSH and GnRH deficiencies. Though GHD was suspected based on height (z-score of - 3.1; see Figure 1), treatment had not been initiated based on the initial management focus being to treat her medulloblastoma.
Slides from the patient's liver biopsy. (a) Low power liver section, (b) ballooning hepatocyte degeneration, a feature of hepatic cell death, and (c) intervening fibrous tissue seen as a terminal stage of liver injury. These all constitute steatohepatis with moderate steatosis.
CRIE2018-4748750.002.jpg
PMC6220405_01_CRIE2018-4748750.002.jpg
fig2
Liver biopsy showed steatohepatitis with bridging fibrosis (Figure 2).
The patient's Quality of Life (QoL) scores with time. QoL-AGHDA: Quality of Life-Assessment of Growth Hormone Deficiency in Adults. QLS: Quality of Life Satisfaction. 1A decrease in score for QoL-AGHDA indicates an improvement in QoL-AGHDA, whereas an increase in QLS indicates an improvement while taking GH therapy.
CRIE2018-4748750.003.jpg
PMC6220405_01_CRIE2018-4748750.003.jpg
fig3
She was now able to work for 20 hours weekly without becoming fully exhausted and her Quality of Life-Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) and Quality of Life Satisfaction (QLS) scores, both questionnaire-based, improved (Figure 3).